The Cancer Drug Fund, a resource set up to improve drug access for patients, lacks effective management, UK’s Public Accounts Committee (PAC) has reported. The government body has said it is "unacceptable" that the government is still unable to properly assess the benefit to patients of the Cancer Drugs Fund.
The fund was established in 2010 by the government to improve access to cancer drugs that otherwise would not be routinely available on the NHS.
While about 80,000 people have received drugs through the Fund, "the Department of Health and NHS England do not have the data needed to assess the impact of the Fund on patient outcomes, such as extending patients’ lives, or to demonstrate whether this is a good use of taxpayers’ money," the report said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze